VY7523 is an investigational recombinant humanized IgG4 monoclonal antibody developed by Voyager Therapeutics in a Phase 1/2 clinical trial for early Alzheimer's disease (AD)[1]. The antibody targets a novel mechanism of neurodegenerative pathology distinct from established amyloid-beta (Abeta) or tau targets[2]. The trial enrolls approximately 52 patients in a multiple ascending dose (MAD) study design.
Voyager Therapeutics is a biotechnology company focused on developing gene therapy and antibody-based treatments for severe neurological diseases. Their platform combines adeno-associated virus (AAV) delivery technology with novel therapeutic antibodies, enabling potent CNS penetration and sustained target engagement[3].
| Parameter | Value |
|---|---|
| Trial ID | NCT06874621 |
| Sponsor | Voyager Therapeutics |
| Phase | Phase 1/2 |
| Status | Active, recruiting |
| Study Type | Interventional |
| Indication | Early Alzheimer's Disease |
| Enrollment | Approximately 52 participants |
| Start Date | 2024 |
| Study Design | Multiple ascending dose (MAD) |
VY7523 is a humanized IgG4 monoclonal antibody designed to target a specific epitope involved in neurodegenerative pathways characteristic of Alzheimer's disease. The antibody-mediated targeting approach enables selective engagement of pathological proteins or aggregates contributing to neuronal dysfunction[4].
While the precise molecular target is proprietary to Voyager's development program, the antibody-based approach suggests engagement with one or more of the following pathogenic mechanisms:
The IgG4 isotype of VY7523 offers specific advantages for CNS therapeutic applications:
Voyager Therapeutics has built a proprietary gene therapy platform based on AAV vector technology capable of crossing the blood-brain barrier and achieving broad CNS transduction[3:1]. While VY7523 is delivered as a traditional monoclonal antibody (not AAV-mediated gene therapy), the company's expertise in CNS antibody engineering informs the antibody design:
Voyager's experience with AAV delivery of therapeutic proteins has informed their approach to antibody engineering for CNS targets:
VY7523 represents a strategic expansion of Voyager's CNS antibody capabilities, complementing their AAV-based gene therapy pipeline for neurodegenerative diseases. The antibody modality offers:
VY7523 enters a rapidly evolving AD antibody therapeutics field marked by recent approvals and clinical advances[8]:
| Therapeutic | Target | Company | Status |
|---|---|---|---|
| Lecanemab | Amyloid-beta protofibrils | Eisai/Biogen | Approved |
| Donanemab | N-terminal pyroglutamate Abeta | Eli Lilly | Approved |
| Aducanumab | Aggregated amyloid-beta | Biogen | Approved |
| Gantenerumab | Fibrillar amyloid-beta | Roche | Phase 3 |
| VY7523 | Novel mechanism | Voyager | Phase 1/2 |
Unlike the amyloid-targeting antibodies that have dominated AD clinical development, VY7523's novel mechanism represents a differentiated approach:
The Phase 1/2 study employs a standard MAD design to establish safety, tolerability, and pharmacokinetics of repeated VY7523 administration:
Phase 1 (Dose Escalation)
Phase 2 (Expansion)
VY7523 represents an important addition to the AD therapeutic pipeline by:
Phase 1/2 trials for novel mechanism AD therapeutics are critical for:
ClinicalTrials.gov NCT06874621. 2025. ↩︎
Voyager Therapeutics Pipeline. 2025. ↩︎
CNS delivery of antibodies and biologics via AAV vectors. Nature Reviews Drug Discovery. 2021. ↩︎ ↩︎
Safety and tolerability of BAN2401 in healthy volunteers. Journal of Alzheimer's Disease. 2016. ↩︎
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. The EMBO Journal. 2002. ↩︎ ↩︎
Amyloid-beta plaques and neurofibrillary tangles as therapeutic targets in Alzheimer's disease. Nature Reviews Neurology. 2021. ↩︎
Monoclonal antibodies for Alzheimer's disease: lessons from amyloid-targeting therapies. Lancet Neurology. 2022. ↩︎
Lecanemab in early Alzheimer's disease. New England Journal of Medicine. 2023. ↩︎
Biomarkers for Alzheimer's disease in 2024. Alzheimer's and Dementia. 2019. ↩︎